- Home
- CTMX vs BLUE Comparison
CTMX vs BLUE Comparison
Compare CTMX & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- BLUE
- Stock Information
- Founded
- CTMX 2008
- BLUE 1992
- Country
- CTMX United States
- BLUE United States
- Employees
- CTMX N/A
- BLUE N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTMX Health Care
- BLUE Health Care
- Exchange
- CTMX Nasdaq
- BLUE Nasdaq
- Market Cap
- CTMX 85.3M
- BLUE 82.2M
- IPO Year
- CTMX 2015
- BLUE 2013
- Fundamental
- Price
- CTMX $0.84
- BLUE $8.35
- Analyst Decision
- CTMX Buy
- BLUE Hold
- Analyst Count
- CTMX 6
- BLUE 9
- Target Price
- CTMX $5.77
- BLUE $49.14
- AVG Volume (30 Days)
- CTMX 1.2M
- BLUE 328.0K
- Earning Date
- CTMX 03-10-2025
- BLUE 11-14-2024
- Dividend Yield
- CTMX N/A
- BLUE N/A
- EPS Growth
- CTMX N/A
- BLUE N/A
- EPS
- CTMX 0.16
- BLUE N/A
- Revenue
- CTMX $126,617,000.00
- BLUE $53,120,000.00
- Revenue This Year
- CTMX $22.55
- BLUE $145.88
- Revenue Next Year
- CTMX N/A
- BLUE $239.89
- P/E Ratio
- CTMX $5.20
- BLUE N/A
- Revenue Growth
- CTMX 33.66
- BLUE 144.50
- 52 Week Low
- CTMX $0.79
- BLUE $5.80
- 52 Week High
- CTMX $5.85
- BLUE $38.40
- Technical
- Relative Strength Index (RSI)
- CTMX 33.95
- BLUE 49.21
- Support Level
- CTMX $0.79
- BLUE $7.96
- Resistance Level
- CTMX $1.17
- BLUE $8.75
- Average True Range (ATR)
- CTMX 0.08
- BLUE 0.69
- MACD
- CTMX -0.03
- BLUE -0.05
- Stochastic Oscillator
- CTMX 13.16
- BLUE 23.72
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.